GM20173
LCL from B-Lymphocyte
Description:
DEAFNESS, AUTOSOMAL RECESSIVE 49; DFNB49
MARVEL DOMAIN-CONTAINING PROTEIN 2; MARVELD2
Repository
|
NIGMS Human Genetic Cell Repository
|
Subcollection |
Heritable Diseases |
Class |
Disorders of Uncertain Biochemical Etiology |
Biopsy Source
|
Peripheral vein
|
Cell Type
|
B-Lymphocyte
|
Tissue Type
|
Blood
|
Transformant
|
Epstein-Barr Virus
|
Sample Source
|
LCL from B-Lymphocyte
|
Race
|
East Indian
|
Ethnicity
|
PAKISTANI
|
Family Member
|
2
|
Relation to Proband
|
father
|
Confirmation
|
Clinical summary/Case history
|
Species
|
Homo sapiens
|
Common Name
|
Human
|
Remarks
|
|
IDENTIFICATION OF SPECIES OF ORIGIN |
Species of Origin confirmed by LINE assay |
|
Gene |
MARVELD2 |
Chromosomal Location |
5q12.3-q14.1 |
Allelic Variant 1 |
610572.0002; DEAFNESS, AUTOSOMAL RECESSIVE 49 |
Identified Mutation |
IVS4+2delTGAG; In 2 Pakistani families with DFNB49 (610513), Riazuddin et al. (Am J Hum Genet 79:1040-1051, 2006) found deletion of nucleotides TGAG at positions 2 through 5 in the donor site of IVS4 of the MARVELD2 gene.
|
Remarks |
Clinically normal of two affected daughters; affected daughter is GM20172; donor subject is heterozygous for a donor site mutation: a deletion of TGAG at positons 2-5 in the cryptic splice-donor site of IVS4 (IVS4+2delTGAG) of the MARVELD2 (TRIC) gene [the mRNA uses the site that introduces 23 bp of intron 4 which results in a premature stop codon (p.K445fsX461)] |
Riazuddin S, Ahmed ZM, Fanning AS, Lagziel A, Kitajiri S, Ramzan K, Khan SN, Chattaraj P, Friedman PL, Anderson JM, Belyantseva IA, Forge A, Riazuddin S, Friedman TB, Tricellulin is a tight-junction protein necessary for hearing American journal of human genetics79:1040-51 2006 |
PubMed ID: 17186462 |
Split Ratio |
1:5 |
Temperature |
37 C |
Percent CO2 |
5% |
Medium |
Roswell Park Memorial Institute Medium 1640 with 2mM L-glutamine or equivalent |
Serum |
15% fetal bovine serum Not Inactivated |
Substrate |
None specified |
Subcultivation Method |
dilution - add fresh medium |
Supplement |
- |
|
|